BACKGROUND: The Cancer Genome Atlas (TCGA) project is a large-scale effort with the goal of identifying novel molecular aberrations in glioblastoma (GBM). METHODS: Here, we describe an in-depth analysis of gene expression data and copy number aberration (CNA) data to classify GBMs into prognostic groups to determine correlates of subtypes that may be biologically significant. RESULTS: To identify predictive survival models, we searched TCGA in 173 patients and identified 42 probe sets (P = .0005) that could be used to divide the tumor samples into 3 groups and showed a significantly (P = .0006) improved overall survival. Kaplan-Meier plots showed that the median survival of group 3 was markedly longer (127 weeks) than that of groups 1 and 2 (47 and 52 weeks, respectively). We then validated the 42 probe sets to stratify the patients according to survival in other public GBM gene expression datasets (eg, GSE4290 dataset). An overall analysis of the gene expression and copy number aberration using a multivariate Cox regression model showed that the 42 probe sets had a significant (P < .018) prognostic value independent of other variables. CONCLUSIONS: By integrating multidimensional genomic data from TCGA, we identified a specific survival model in a new prognostic group of GBM and suggest that molecular stratification of patients with GBM into homogeneous subgroups may provide opportunities for the development of new treatment modalities.
BACKGROUND: The Cancer Genome Atlas (TCGA) project is a large-scale effort with the goal of identifying novel molecular aberrations in glioblastoma (GBM). METHODS: Here, we describe an in-depth analysis of gene expression data and copy number aberration (CNA) data to classify GBMs into prognostic groups to determine correlates of subtypes that may be biologically significant. RESULTS: To identify predictive survival models, we searched TCGA in 173 patients and identified 42 probe sets (P = .0005) that could be used to divide the tumor samples into 3 groups and showed a significantly (P = .0006) improved overall survival. Kaplan-Meier plots showed that the median survival of group 3 was markedly longer (127 weeks) than that of groups 1 and 2 (47 and 52 weeks, respectively). We then validated the 42 probe sets to stratify the patients according to survival in other public GBM gene expression datasets (eg, GSE4290 dataset). An overall analysis of the gene expression and copy number aberration using a multivariate Cox regression model showed that the 42 probe sets had a significant (P < .018) prognostic value independent of other variables. CONCLUSIONS: By integrating multidimensional genomic data from TCGA, we identified a specific survival model in a new prognostic group of GBM and suggest that molecular stratification of patients with GBM into homogeneous subgroups may provide opportunities for the development of new treatment modalities.
Authors: Anjan Misra; Malgorzata Pellarin; Lily Hu; Sandeep Kunwar; Mark Perhouse; Kathleen R Lamborn; Dennis F Deen; Burt G Feuerstein Journal: Genes Chromosomes Cancer Date: 2006-01 Impact factor: 5.006
Authors: Howard Colman; Li Zhang; Erik P Sulman; J Matthew McDonald; Nasrin Latif Shooshtari; Andreana Rivera; Sonya Popoff; Catherine L Nutt; David N Louis; J Gregory Cairncross; Mark R Gilbert; Heidi S Phillips; Minesh P Mehta; Arnab Chakravarti; Christopher E Pelloski; Krishna Bhat; Burt G Feuerstein; Robert B Jenkins; Ken Aldape Journal: Neuro Oncol Date: 2009-10-20 Impact factor: 12.300
Authors: Marta M Alonso; Juan Fueyo; Jerry W Shay; Kenneth D Aldape; Hong Jiang; Ok-Hee Lee; David G Johnson; Jing Xu; Yasuko Kondo; Takao Kanzawa; Satoru Kyo; B Nebiyou Bekele; Xian Zhou; Janice Nigro; J Matthew McDonald; W K Alfred Yung; Candelaria Gomez-Manzano Journal: J Natl Cancer Inst Date: 2005-11-02 Impact factor: 13.506
Authors: J Graeme Hodgson; Ru-Fang Yeh; Amrita Ray; Nicholas J Wang; Ivan Smirnov; Mamie Yu; Sujatmi Hariono; Joachim Silber; Heidi S Feiler; Joe W Gray; Paul T Spellman; Scott R Vandenberg; Mitchel S Berger; C David James Journal: Neuro Oncol Date: 2009-01-12 Impact factor: 12.300
Authors: Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert Journal: Brain Date: 2007-09-04 Impact factor: 13.501
Authors: Amy K LeBlanc; Christina Mazcko; Diane E Brown; Jennifer W Koehler; Andrew D Miller; C Ryan Miller; R Timothy Bentley; Rebecca A Packer; Matthew Breen; C Elizabeth Boudreau; Jonathan M Levine; R Mark Simpson; Charles Halsey; William Kisseberth; John H Rossmeisl; Peter J Dickinson; Timothy M Fan; Kara Corps; Kenneth Aldape; Vinay Puduvalli; G Elizabeth Pluhar; Mark R Gilbert Journal: Neuro Oncol Date: 2016-05-14 Impact factor: 12.300
Authors: Fabiana Marcelino Meliso; Christopher G Hubert; Pedro A Favoretto Galante; Luiz O Penalva Journal: Hum Genet Date: 2017-06-12 Impact factor: 4.132
Authors: George S Krasnov; Alexey A Dmitriev; Nataliya V Melnikova; Andrew R Zaretsky; Tatiana V Nasedkina; Alexander S Zasedatelev; Vera N Senchenko; Anna V Kudryavtseva Journal: Nucleic Acids Res Date: 2016-01-14 Impact factor: 16.971